Examiner Cite

5

Kind

publisher, city and/or country where published.

Remove

Pages,Columns,Lines where

Relevant Passages or Relevant

Τ۶

	Application Number		10576522		
	Filing Date		2006-04-19		
NFORMATION DISCLOSURE	First Named Inventor Nanc		cy Auestad		
TATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		1618		
NOTION SUBMISSION UNION 57 OF K 1.337	Examiner Name	Ebrah	ahim, Nabila G.		
	Attorney Docket Numb	er	7278USO1		

U.S. PATENTS

Name of Patentee or Applicant

initial.	NO			Code			of cited Doci	ıment	Figur	es Appear	
	1										
If you wisl	h to a	dd a	additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add	
				U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite	No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pat of cited Docu	entee or Applicant ument	Rele	es,Columns,Lines where want Passages or Relev res Appear	
	1		20020025983	A1	2002-0	2-28	Horrobin				
If you wish	h to a	dd a	additional U.S. Pub	lished Ap	plication	citatio	n information p	please click the Ad	d butto	on. Add	
					FORE	GN PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No		reign Document umber ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TS
	1										
If you wis	h to a	dd a	dditional Foreign F	atent Do	cument	citation	information p	lease click the Add	butto	n Add	_
				NON	-PATE	NT LITE	RATURE DO	CUMENTS		Remove	_

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

Examiner Cite

Initials* No

	KOLETZKO, ET AL. "FETTE IN DER ERNAHRUNG VON NEUGEBORENEN MIT NIEDRIGEM GEBURTSGEWICHT, MONATSCORNET FUER KINDERHEILKUNGE, SPRINGER VERLAG, VOL. 7, SUPPL. 2, NO. 143, FAGES 98-184 (1998).					
	2	International Preliminary Report on Patentability for PCTI/USO/4/42770, dated June 20, 2006.				
If you wish to add additional non-patent literature document citation information please click the Add button Add						

Examiner Signature Date Considered Date Considered |

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GDV</u> or MPEP 901 Dt. ² Entire office that issued the document, by the two-letter code (WIPO Standard ST 3). ³ For Japanese peter documents, the adulation of the year of the steps of the Circumstant and adulation of the year of the steps of the Circumstant and the See adulation of the peter document. Which of document for the year potential synthesis as adulated to the document under WIPO Securities 201. "Applicant to be passed as check many here."

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10576522		
Filing Date First Named Inventor Nancy			2006-04-19		
		Nanc	Auestad		
	Art Unit		1618		
	Examiner Name Ebrah		im, Nabila G.		
	Attorney Docket Number		7278USO1		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith
- SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Christopher M. Goff/	Date (YYYY-MM-DD)	2011-10-31
Name/Print	Christopher M. Goff	Registration Number	41,785

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursyant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.